(Q47950164)

7 February 2018

title

TLR2-targeted secreted proteins from Mycobacterium tuberculosis are protective as powdered pulmonary vaccines (English)

1 reference

7 February 2018

Mycobacterium tuberculosis

main subject

0 references

0 references

Hak-Kim Chan

5

0 references

Nicholas P West

object named as

Nicholas P West

7

0 references

author name string

Anneliese S Tyne

1

1 reference

7 February 2018

John Gar Yan Chan

2

1 reference

7 February 2018

Erin R Shanahan

3

1 reference

7 February 2018

Ines Atmosukarto

4

1 reference

7 February 2018

Warwick J Britton

6

1 reference

7 February 2018

language of work or name

English

0 references

publication date

20 July 2013

1 reference

7 February 2018

published in

Vaccine

1 reference

7 February 2018

volume

31

1 reference

7 February 2018

issue

40

1 reference

7 February 2018

page(s)

4322-4329

1 reference

7 February 2018

Future Vaccination Strategies against Tuberculosis: Thinking outside the Box

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.022

The success and failure of BCG - implications for a novel tuberculosis vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.022

A booster vaccine expressing a latency-associated antigen augments BCG induced immunity and confers enhanced protection against tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.022

A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.022

The candidate tuberculosis vaccine Mtb72F/AS02 in PPD positive adults: a randomized controlled phase I/II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.022

Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.022

Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.022

The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.022

The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.022

Targeting the deep lungs, Poloxamer 407 and a CpG oligonucleotide optimize immune responses to Mycobacterium tuberculosis antigen 85A following pulmonary delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.022

Effects of lung surfactants on rifampicin release rate from monodisperse rifampicin-loaded PLGA microspheres.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.022

Pulmonary vaccine delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.022

Nanocarriers targeting dendritic cells for pulmonary vaccine delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.022

The immune response in tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.022

Prophylactic and therapeutic implications of toll-like receptor ligands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.022

Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.022

Fatal Mycobacterium tuberculosis infection despite adaptive immune response in the absence of MyD88.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.022

Interleukin-1 signaling is essential for host defense during murine pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.022

Mycobacterium bovis bacilli Calmette-Guerin regulates leukocyte recruitment by modulating alveolar inflammatory responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.022

Activation of Toll-like receptor 2 on human tracheobronchial epithelial cells induces the antimicrobial peptide human beta defensin-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.022

Synchronization of dendritic cell activation and antigen exposure is required for the induction of Th1/Th17 responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.022

Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.022

Toll-dependent selection of microbial antigens for presentation by dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.022

Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.022

Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.022

Immunological diversity within a family of cutinase-like proteins of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.022

Cutinase-like proteins of Mycobacterium tuberculosis: characterization of their variable enzymatic functions and active site identification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.022

Cutinase-like protein-6 of Mycobacterium tuberculosis is recognised in tuberculosis patients and protects mice against pulmonary infection as a single and fusion protein vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.022

The secreted lipoprotein, MPT83, of Mycobacterium tuberculosis is recognized during human tuberculosis and stimulates protective immunity in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.022

Prospects for Tuberculosis Elimination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.022

Evaluation of the safety and immunogenicity of a candidate tuberculosis vaccine, MVA85A, delivered by aerosol to the lungs of macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.022

The delivery site of a monovalent influenza vaccine within the respiratory tract impacts on the immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.022

Immunization by a bacterial aerosol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.022

Dry-powder pulmonary insufflation in the mouse for application to vaccine or drug studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.022

A comparison between spray drying and spray freeze drying to produce an influenza subunit vaccine powder for inhalation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.022

Inhaled mannitol for the treatment of cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.022

Physicochemical stability of crystalline sugars and their spray-dried forms: dependence upon relative humidity and suitability for use in powder inhalers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.022

Poly-L-arginine synergizes with oligodeoxynucleotides containing CpG-motifs (CpG-ODN) for enhanced and prolonged immune responses and prevents the CpG-ODN-induced systemic release of pro-inflammatory cytokines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.022

Designing vaccines based on biology of human dendritic cell subsets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.022

10.1016/J.VACCINE.2013.07.022

7 January 2021

Identifiers

DOI

1 reference

7 February 2018

1 reference

7 February 2018